THE IMPACT OF CMV-SEROPOSITIVITY ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR IN AML AND MDS PATIENTS (EBMT 2026) - Mar 14, 2026 - Abstract #B094; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Our findings suggest that, even in the letermovir era, the CMV serostatus may still affect RFS. Furthermore, we found no evidence that prophylaxis with letermovir or CMV infection are relevant risk factors for relapse in our large cohort of AML and MDS patients. However, further studies are needed to confirm these findings and to evaluate the possible impact of donor CMV serostatus and the underlying mechanisms."
Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Transplantation • CD4 • CD8
|
|
Lina Kolloch1; Judith Boschke2; Christian Reicherts1; Julian Ronnacker1; Hanna Schneider1; Jörn Albring1; Julia Marx1; Eva Eßeling1; Georg Lenz1; Matthias Stelljes1
|